Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
For investors tracking breakthrough oncology pipelines, Fennec Pharmaceuticals’ disclosures can stretch beyond 300 pages of trial data, FDA milestones, and royalty clauses. Finding when a Phase III expense hits the P&L or when directors exercise options is tough. Fennec Pharmaceuticals SEC filings explained simply starts here.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, DEF 14A, and Form 4 the instant it posts to EDGAR. The platform delivers Fennec Pharmaceuticals earnings report filing analysis minutes after the document drops, highlights pivotal PEDMARK sales trends in the latest Fennec Pharmaceuticals quarterly earnings report 10-Q filing, and alerts you to Fennec Pharmaceuticals Form 4 insider transactions real-time. Our concise notes turn dense scientific language into actionable facts, so understanding Fennec Pharmaceuticals SEC documents with AI becomes routine.
Need a deeper dive? Compare R&D burn rates across quarters, review license-fee milestones, or monitor Fennec Pharmaceuticals executive stock transactions Form 4 before FDA meetings. Our summaries link directly to the sections that matter—risk factors on ototoxicity prevention, cash-runway forecasts, and royalty obligations. You can also pull the Fennec Pharmaceuticals annual report 10-K simplified for long-term strategy, scan the Fennec Pharmaceuticals proxy statement executive compensation to see how leadership incentives align with clinical success, or read the Fennec Pharmaceuticals 8-K material events explained whenever new trial data or partnership news surfaces.
Fennec Pharmaceuticals Inc. (FENC) – Form 144 filing discloses that insider Rostislav Raykov has notified the SEC of his intent to sell up to 10,000 common shares through Morgan Stanley Smith Barney on or after 03 July 2025. At the 30 June 2025 closing price used in the filing, the aggregate market value of the proposed sale is $86,102, equivalent to roughly 0.036 % of the 27.6 million shares outstanding.
The shares stem from recently vested restricted-stock grants acquired on 16 May 2025 (7,570 sh) and 30 June 2025 (2,430 sh). The filing also details that Raykov has already disposed of 46,667 shares between 4 April and 5 June 2025 for total gross proceeds of approximately $295,398.
Rule 144 notices do not guarantee execution, but repeated insider sales within a short window can influence market sentiment. Nevertheless, the cumulative volume over the past quarter plus the planned sale (≈56,667 shares) remains below 0.21 % of outstanding shares, suggesting limited dilution or supply pressure.
Fennec Pharmaceuticals Inc. (FENC) filed a Form 4 disclosing that Director Rosty Raykov acquired 5,208 common shares on 06/30/2025. The shares were received at $0 cost as they were released from restriction on previously granted awards dated 03/31/2023 and 05/16/2024. Following the vesting event, Raykov’s total direct beneficial ownership increased to 70,670 shares. No derivative securities were exercised or disposed of, and there were no open-market sales associated with this filing.
The transaction is relatively small in absolute terms and represents an internal vesting rather than a cash purchase; however, the absence of sales and the continued accumulation of equity may be read as a signal of ongoing alignment between the director and shareholders.
On 07/01/2025, Fennec Pharmaceuticals Inc. (FENC) filed a Form 4 reporting that Chief Financial Officer Robert Andrade acquired 2,431 common shares on 06/30/2025.
The acquisition reflects the release of restrictions on equity awards originally granted on 03/31/2023 and 05/16/2024. Because the shares vested at a price of $0, the event represents routine compensation vesting rather than an open-market purchase or sale.
After the transaction, Andrade directly holds 163,382 FENC common shares. No derivative security activity was disclosed.
This filing signals a modest increase in the executive’s unrestricted stake and indicates continued alignment with shareholder interests, but the size of the release is unlikely to have a material impact on the company’s valuation or trading dynamics.
FAQ
What is the current stock price of Fennec Pharmaceuticals (FENC)?
What is the market cap of Fennec Pharmaceuticals (FENC)?
What is the primary focus of Fennec Pharmaceuticals Inc?
What is PEDMARK?
How does Fennec generate revenue?
What clinical evidence supports the use of PEDMARK?
Which markets does Fennec primarily operate in?
How does Fennec differentiate itself from its competitors?
What is the significance of Fennec's licensing partnerships?
How does the company maintain industry credibility?
